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Endothelin-1 (ET-1) plays a pivotal role in vasoconstriction, fibrosis, and inflammation, the key features of systemic sclerosis (SSc).
ET-1 receptors (ETA and ETB) are expressed on endothelial cells, smooth muscle cells, and fibroblasts, but their presence on
immune cells has not been deeply investigated so far. Endothelin receptors antagonists such as bosentan have beneficial effects
on vasoconstriction and fibrosis, but less is known about their potential anti-inflammatory effects. We studied the expression of
ET-1 receptors on immune cells (T and B lymphocytes, monocytes, and neutrophils) and the link between ET-1 and inflammation
in patients with SSc. We show here that ET-1 exerts a proinflammatory effect in CD4+ T cells, since it induces an increased IFN-𝛾
production; preincubation with antagonists of both receptors reduces IFN-𝛾 production. Moreover, following ET-1 stimulation,
neutrophils produce proinflammatory mediators, thus amplifying the effects of activated CD4+ T cells. Our data indicate that
ET-1 system is involved in the pathogenesis of inflammation and fibrosis typical of SSc, through the activation of T lymphocytes
and neutrophils and the consequent release of proinflammatory and profibrotic cytokines. These findings suggest that dual
ET-1 receptors antagonist therapy, besides its effect on vasculopathy, has a profound impact on the immune system favouring
antiinflammatory and antifibrogenic effects.
1. Introduction
Systemic sclerosis (SSc) is an autoimmune disease that
involves the connective tissue of skin and internal organs
with a remarkable heterogeneity in the disease course and
affected organs, resulting in high morbidity and mortality.
The disease is characterized by vascular dysfunction and
injury and by overproduction and accumulation of collagen
and other extracellular matrix proteins, resulting in the
thickening of the skin and fibrosis of the affected organs
[1, 2].The pathogenetic mechanisms involve three interactive
components represented by severe and diffuse endothelial
cell damage, immune system dysfunction, and fibroblasts
activation.
Endothelin-1 (ET-1) has been described to play a role in
fibrosis, angiogenesis, and inflammation, all major features
of SSc [3, 4]. Indeed ET-1 level is elevated in the serum and
tissues of SSc patients, especially in diffuse SSc patients, and
serum levels have been shown to correlate with the extent of
vascular damage and cutaneous fibrosis [3–6].
ET-1 is the major isoform of three endothelin isoforms
and is a soluble mediator that exerts a potent vasoconstrictor
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effect [7]. ET-1 has been firstly described in endothelial cells
and in vascular smooth muscle cells, where hypoxia, cold
exposure, low shear stress, angiotensin II, cytokines, and
growth factors may facilitate its production [7, 8]. Many
cells can produce ET-1 including fibroblasts and myofibrob-
lasts, mast cells, monocytes/macrophages, polymorphonu-
clear leukocytes, and dendritic cells [9–14]. Transforming
growth factor- (TGF-) 𝛽 and ET-1 itself, with an autocrine
loop, are able to induce ET-1 production in fibroblasts and
myofibroblasts [9, 15].
There are at least three ET-1 receptors: ETA, ETB, and
ETC [8, 16, 17]; however, the function of ETC is poorly
known; ETA and ETB are expressed on the majority of
cells that actively contribute to SSc pathogenesis, such as
fibroblasts, myofibroblasts, vascular smoothmuscle cells, and
platelets, while endothelial cells selectively express ETB [6–
8, 16]. Upon binding receptors on vascular smooth muscle
cells, ET-1 is able to induce vasoconstriction, cell growth,
and proliferation, leading to lumen narrowing at arterial
and arteriolar level [18–20]. Moreover, ET-1 facilitates fibrob-
lasts transdifferentiation into myofibroblasts and induces the
production of both collagen and ET-1 probably through an
autocrine mechanism [9, 15, 21–26].
There is increasing evidence that ET-1 may play a pivotal
role in inflammation in several human diseases including
chronic renal disease, asthma [27–30], and sepsis (reviewed
in [44]); however, themechanisms by which ET-1 induces the
activation of the innate and adaptive immune systems have
not been fully elucidated so far. Saleh and Pollock suggested
that ET-1 can directly activate neutrophils and can induce
the production of chemoattractant factors, such as monocyte
chemoattractant factor-1 (MCP-1), and the synthesis of cell
adhesion molecules, such as soluble intercellular adhesion
molecule-1 (ICAM-1) [27].Moreover ET-1 seems to be associ-
atedwith the activation of transcription factors such asNF-𝜅B
and the production of proinflammatory cytokines including
tumor necrosis factor-alpha (TNF-𝛼), interleukin- (IL-) 1,
and IL-6 [31]. Little is known on ET-1 receptors expression on
immune cells with the exception of a few data on cells of the
innate immune system, such as dendritic cells andmonocytes
[10–14, 32]. The expression of ET-1 receptors on adaptive
immune effectors cells (T and B lymphocytes) has not been
investigated so far and therefore little is knownon the possible
role of ET-1 as a mediator of inflammatory responses.
In the last decade, orally active ET-1 receptor antago-
nists (ERAs) were developed and approved for clinical use.
Two orally active ERAs are currently approved, the dual
receptor antagonist, bosentan, and the selective ETA receptor
antagonist, ambrisentan [33–35]. Both ERAs are used in
the treatment of pulmonary arterial hypertension (PAH)
whereas only bosentan has been shown to be effective in the
prevention of new scleroderma-related digital ulcers (DUs)
[36]. In addition to the effects on vasculature and fibrosis
[36–38], it has been recently reported that ET-1 blockade
using bosentanmay also have some anti-inflammatory effects
([39], reviewed in [44]). In particular, bosentan seems to
be able to suppress the ET-1-induced production of TNF-𝛼
and other proinflammatory mediators by monocytes in vitro
[11]. In vivo, bosentan significantly reduces IL-6, ICAM-1,
and pro-brain natriuretic peptide (pro-BNP) serum levels in
patients with PAH [40] and leads to the normalization of
soluble adhesion molecules in SSc-associated PAH [40, 41].
Inflammation is deeply involved both in the early phase of
SSc pathogenesis and in the progression of vascular damage
and fibrosis. Therefore, we aimed at investigating the role of
ET-1 as possible mediator of inflammatory damage in SSc.
Since immune effectors cells, such as T and B lymphocytes,
monocytes, and neutrophils, are important players of inflam-
mation in SSc, we aimed at clarifying the possible role played
by ET-1 receptors in immune cells activation.
In this paper, we studied the presence of ET-1 receptors
on T and B lymphocytes, monocytes, and neutrophils by
FACS analysis. We also analysed the effects of ET-1 receptors
engagement in order to verify the proinflammatory activity
of ET-1 and the potential anti-inflammatory effects of ERAs.
2. Materials and Methods
2.1. Patients and Controls. We studied a cohort of 41 patients
(5 males and 36 females, mean age: 57 ± 14 years) affected
by SSc, attending the Unit of Autoimmunity Diseases at
the University Hospital of Verona, Italy. SSc diagnosis was
performed in accordance with the American College of
Rheumatology/European League against Rheumatism classi-
fication criteria for systemic sclerosis [42, 43].
Patients were classified according to the following clinical
features: limited (lSSc) or diffuse (dSSc) cutaneous form of
SSc (32 patients with lSSc and 9 with dSSc) and presence or
absence of ischemic digital ulcers, PAH, and interstitial lung
disease (ILD). Ten patients were on bosentan therapy because
of digital ulcers or PAH. Twenty age and sex matched healthy
subjects were used as control group.
Blood samples (20mL) were collected in heparinized
Falcon tubes (Becton Dickinson, NJ, USA) from both
patients and control subjects. A written informed consent
was obtained from all the participants to the study and
the study was approved by the local ethical committee. All
clinical investigations have been conducted according to the
principles expressed in the Helsinki declaration.
2.2. Isolation of Peripheral Blood Mononuclear Cells and
Flow-Cytometry. Blood samples obtained from patients and
controls were dilutedwith 20mL of phosphate buffered saline
(PBS) solution. Mononuclear cells isolated by density gradi-
ent centrifugation using lymphoprep Ficoll-Isopaque (Axis-
Shield, Oslo, Norway) were washed twice with PBS and sus-
pended in tubes containing 1 million cells for flow-cytometry
(FACS) analysis. Analysis ofmonocytes and lymphocytes was
carried out in different tubes; cells used for monocytes stain-
ing were preincubated with mouse serum (DAKO, Glostrup,
Denmark) for 10 minutes at room temperature. Each sample
was incubated for 1 hour at 4∘C with eitherrabbit polyclonal
anti-ETA (Acris Antibodies GmbH, Herford, Germany) or
sheep polyclonal anti-ETB (LifespanBiosciences, Seattle,WA,
USA) antibodies. Phycoerythrin- (PE-) conjugated goat anti-
rabbit IgGmonoclonal (0.25mg/mL)was used as a secondary
antibody for ETA (R&D Systems, Minneapolis, MN, USA)
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and PE-conjugated donkey anti-sheep IgG monoclonal
(0.2mg/mL) was used as a secondary antibody for ETB (R&D
Systems) and incubated for 30 minutes at 4∘C. Samples were
also stained for 20 minutes at room temperature in a dark
room with allophycocyanin- (APC-) conjugated anti-CD3
or anti-CD14 or anti-CD19 antibodies (BD Biosciences, San
Jose, CA, USA). After labeling, samples were acquired in a
FACSCanto cytometer (Becton Dickinson).The sensitivity of
fluorescence detectors was set and monitored using Calibrite
Beads (Becton Dickinson) according to the manufacturer’s
recommendations; 20.000 CD3+, CD14+, or CD19 cells per
sample were, respectively, acquired in live gating. FlowJo
8.8.2 software (Tree Star, Ashland, OR) was used to analyze
the data. Expression of ETA or ETB was calculated as the
difference between mean fluorescence intensity (MFI) of
cells stained with primary plus secondary antibodies and
MFI of their negative control (cells stained with secondary
antibodies): ΔMFI.
2.3. T Cells Stimulation. In order to assess receptors expres-
sion on activated CD4+ and CD8+ T cells, PBMC isolated
from 4 patients and 4 controls were stimulated for 24
hours with anti-CD3/CD28 antibodies coated microbeads-
Dynabeads Human T-Activator (Dynal, Oslo, Norway),
according to the manufacturer’s recommendations. Cells
were cultured in RPMI-1640-GlutaMAX-I, supplemented
with 10% fetal calf serum (FCS), 100U/mL penicillin, and
100 microg/mL streptomycin (all purchased from Life Tech-
nologies, Carlsbad, CA). In order to identify CD4+ and
CD8+ T lymphocytes, we incubated cells with a mixture of
the following antibodies: PerCp-conjugated anti-CD3, APC-
H7-conjugated anti-CD4, and APC-conjugated anti-CD8
antibodies. Activated cells were detected by incubating cells
with FITC-conjugated anti-CD25 antibodies; all reagents
were purchased from BD Biosciences. Cells were previously
stained with anti-ETA and anti-ETB primary and secondary
antibodies as previously described and sampleswere acquired
on a FACSCanto cytometer FlowJo 8.8.2 software was used to
analyse data. The variation in receptors surface exposure was
expressed as the difference between activated cells MFI and
unstimulated cells MFI (ΔΔMFI).
2.4. Isolation of T CD4+ Cells. Mononuclear cells from
healthy donors buffy coats were isolated by density gradient
centrifugation using lymphoprep Ficoll-Isopaque. CD4+ T
cells were obtained through negative selection using CD4+ T
Cell Isolation Kit II (Miltenyi Biotec) and MidiMACS Start-
ing Kit, including MACS LD column and MACS Separator
(Miltenyi Biotec), following manufacturer’s instructions.
2.5. RNA Extraction and RT-PCR from CD4+ T Cells. Total
RNA was extracted from CD4+ T cells using TRIzol Reagent
(Gibco BRL, Billings, MT, USA) following themanufacturer’s
protocol. RNA was previously treated with DNAse I (Invitro-
gen).
First-strand cDNAwas carried out using the Super Script
III System (Invitrogen, Carlsbad, CA, USA), with random
hexamers, according to the manufacturer’s recommenda-
tions. Fibroblasts cDNA was used as positive control for the
detection of ETA- and ETB-coding mRNA.
CD4+ T cells and fibroblasts cDNA were amplified with









(Sigma-Aldrich, Saint Louis, MO, USA).
Vimentin was used as PCR reaction-control. Amplifica-
tion was performed using the AmpliTaq Gold PCR Mas-
terMix system (Applied Biosystems, Foster City, CA, USA).
cDNA was amplified using the primers specific for ETA and
ETB receptors and for vimentin using the GeneAmp PCR
System 9700 thermal cycler (Applied Biosystems) and the
amplification reaction was carried out as follows: 10 minutes
at 95∘C followed by 40 cycles of denaturation (45 seconds
at 94∘C), annealing (30 seconds at 53∘C for ETA and 55
∘C
for ETB and for vimentin), and extension (1 minute at 72
∘C
and 7 minutes at 72∘C to stop reaction). Amplicons (length:
447 bp for ETA, 558 bp for ETB, and 266 bp for vimentin)were
run on agarose gel (1.5%) and revealed using VersaDoc video
documentation system (Bio Rad, Hercules, CA, USA).





Stimulation. In order to study the
cytokine production in response to ETA and ETB stimulation
by ET-1 inCD4+T cells, we seededCD4+ cells inmicroplates:
1 million CD4+ T cells per well were seeded in 24-well plates
and different conditions were carried out in duplicate. Cells
were incubated (a) without ET-1 and receptors antagonists
(control sample); (b) with ET-1 alone; (c) with ETA antagonist
(BQ123) and ET-1; (d) with ETB antagonist (BQ788) and ET-
1; (e) with BQ123 plus BQ788 and ET-1. Cells were incubated
with BQ123 and BQ788 at the concentration of 10−6M for
45 minutes and with ET-1 at concentration of 10−7M for 24
hours. All reagents were purchased from Sigma-Aldrich.
We then measured interferon- (IFN-) 𝛾, IL-4, and IL-17
concentrations in cell culture supernatants by enzyme-linked
immunosorbent assay (ELISA) (Quantikine Human IFN-𝛾
Immunoassay, Quantikine Human IL-4 Immunoassay, and
Quantikine Human IL-17 Immunoassay, resp., obtained from
R&D Systems), following the manufacturer’s instructions.
Sunrise absorbance reader for microplates (Tecan, Salzburg,
Austria) was used to determine optical density for each
sample.
2.7. Isolation of Neutrophils, Flow-Cytometry, and RT-PCR.
We isolated neutrophils from healthy donors buffy coat in
order to study surface expression of ETA and ETB by flow-
cytometry and the transcripts for ETA and ETB by RT-
PCR. Highly purified granulocytes (neutrophils > 96.5%)
were isolated and prepared under endotoxin-free conditions
using lymphoprep Ficoll-Isopaque. Neutrophils were further
enriched by positively removing all contaminating cells with
mAb against CD3, CD56, CD19, CD36, CD49d, and Gly-A
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Table 1: ETA and ETB expression on T and B cells, monocytes, and neutrophils in healthy controls and SSc patients.
ET-1 receptors T lymphocytes B lymphocytes Monocytes Neutrophils
ETA ETB ETA ETB ETA ETB ETA ETB
Healthy controls
(𝑛 = 20) 110.45 ± 35.89 49.23 ± 29.16 269.75 ± 37.14 150.75 ± 26.42 188.4 ± 35.61 98.74 ± 54.66 191.65 ± 42.61 92.54 ± 50.89
SSc patients
(𝑛 = 41) 100.61 ± 45.21 46.85 ± 29.78 253.5 ± 40.54 161.33 ± 43.97 212.24 ± 64.27 91.14 ± 29.16 205.74 ± 59.67 88.34 ± 36.78
Data are expressed as mean ± standard deviation of ΔMFI determined by FACS analysis.
using a custom-made Easy-Sep kit (StemCell Technologies,
Vancouver, BC, Canada) to reach more than 99,7% purity.
One million neutrophils were suspended in tubes for FACS
analysis. Staining for ETA- and ETB was carried out as already
described. RNA extraction and RT-PCR were performed as
previously described.
2.8. Analysis of Cytokines and MMP-9 in the Supernatants of
Neutrophils Stimulated with ET-1. Neutrophils were seeded
in microplates and incubated with or without 100 ng/mL
Ultrapure E. coli lipopolysaccharide (LPS) (Invivogen, San
Diego, CA) and with or without ET-1. Therefore we used
4 different conditions: (a) neutrophils without any stimulus
as negative control, (b) neutrophils incubated with ET-1, (c)
neutrophils incubated with LPS alone, (d) and neutrophils
incubated with both ET-1 and LPS. Cells were cultured in
RPMI-1640-GlutaMAX-I, supplemented with 10% fetal calf
serum (FCS), 100U/mL penicillin, and 100microg/mL strep-
tomycin. Interleukin-8, TNF-𝛼, vascular endothelial growth
factor (VEGF), IFN-𝛾, IL-17, and matrix metallopeptidase 9
(MMP-9) released in the supernatants of cultured neutrophils
were assessed by ELISA at two different time points (3
and 10 hours). Quantikine Human Immunoassay for the
selected molecules was purchased from R&D Systems. Sun-
rise absorbance reader for microplates was used to determine
optical density for each sample.
2.9. Statistical Analysis. All the calculations were performed
with SPSS 21.0 statistical package (SPSS Inc., Chicago, IL,
USA). All the results are expressed as ΔMFImean ± standard
deviation. Quantitative data were assessed using Student’s 𝑡-
test. Correlations between ET-A and ET-B cell surface expres-
sion and clinical features were assessed with nonparametric
test and multivariate analysis. A value of 𝑃 < 0.05 was
considered statistically significant.
3. Results
3.1. ET-1 Receptors Expressed by Immune Effector Cells. T and
B lymphocytes as well as monocytes and neutrophils express
ETA and ETB on their surface, using FACS analysis; the data
were obtained as a difference of mean fluorescence intensity
between samples incubatedwith primary and secondary anti-
bodies and their negative controls incubated with secondary
antibody alone (Figure 1). In addition some of the data were
validated by reverse transcription-PCR in CD4+ T cells and
neutrophils (Figure 2).
In both patients and controls, T lymphocytes and mono-
cytes showed a higher surface expression of ETA (patients:
ΔMFI = 100.61 ± 45.21 and 212.24 ± 64.27, resp.; controls:
ΔMFI = 110.45 ± 35.89 and 188.4 ± 35.61, resp.) when
compared to ETB (patients: 46.85 ± 29.78 and 91.14 ± 27.44,
resp.; controls:ΔMFI = 49.23±29.16 and 98.74±54.66, resp.)
(𝑃 < 0.001) (Table 1).
These data indicate that surface ET-1 receptors distribu-
tion on T cells and monocytes of SSc patients is similar to the
one observed in healthy donors.
Patients affected by dSSc showed a lower ETB surface
expression on T cells when compared to patients affected
by lSSc (28.6 ± 17.9 versus 51.9 ± 31.1) (𝑃 < 0.01);
a similar pattern of surface expression was observed on
monocytes (74.4 ± 29.6 versus 97.2 ± 24.5) (𝑃 < 0.05). No
significant difference in ETA expression by T lymphocytes
and monocytes was observed in the diffuse or limited form
of disease (94.8 ± 48.2 versus 99.1 ± 42.1 and 251.2 ± 116.3
versus 199.3 ± 34.5, resp.).
ETA and ETB surface expression were not modified by
bosentan treatment, both on T cells (ETA: 97.9 ± 52 versus
102.6 ± 44.3; ETB: 47.9 ± 17.7 versus 47.6 ± 32.3) and on
monocytes (ETA: 240.7±130.6 versus 205.1±34.9; ETB: 89.6±
22.9 versus 93.1±27.7), suggesting that bosentan therapy does
not induce an increased ET-1 receptors expression.
ETA andETB surface expression onT cells andmonocytes
did not correlate with the presence or absence of DUs (T cells:
121.4 ± 69 versus 98.8 ± 41.6 and 40.8 ± 20.1 versus 48.6 ± 31,
resp.; monocytes: ETA: 221 ± 4.3 versus 211.3 ± 69.6; ETB:
80.4 ± 25.3 versus 93.6 ± 27.5) (Table 2).
Patients with PAH had a lower ETB surface expression
on monocytes when compared to patients without PAH,
although the difference was not statistically significant (77.2±
23.4 versus 96.9 ± 27.3); this difference was significant when
considering patients with the limited subset of the disease
(77.6 ± 17.6 versus 102.3 ± 24.4; 𝑃 < 0.05) (Table 2).
Furthermore, ETA expression was lower on T cells of
lSSc patients with ILD when compared to T cells of patients
without ILD (77.8 ± 34.2 versus 111.6 ± 43.9; 𝑃 < 0.05)
(Table 2).
ETA and ETB expression on B lymphocytes were similar
in patients and healthy donors (Table 1). In SSc patients
ETA surface expression was higher than ETB and was not
influenced by the treatment with bosentan (ETA: 281.33 ±
43.47 and ETB: 161.33± 43.97; 𝑃 < 0.05 versus ETA: 270.00±
28.16 and ETB: 171.33 ± 35.47; 𝑃 < 0.05). ETA and ETB
surface expression were similar in the diffuse or limited form



































































































































Figure 1: ETA and ETB expression by cells obtained from SSc patients.The quantification of receptors expression by T (a) and B lymphocytes
(b), monocytes (c), and neutrophils (d) is represented by the difference of fluorescence intensity between the sample (continuous line) and
its negative control (dotted line). The profile of one of 41 SSc patients is shown. All the other patients had a similar behaviour.
1 2 3 4 5 6 7
(a)
2 3 41 5
(b)
2 3 41 5
(c)
Figure 2: ETA and ETB transcripts amplified by RT-PCR in fibroblasts, CD4+ T lymphocytes, activated CD4+ T cells, and neutrophils. ETA
corresponds to a molecular weight of 446 bp and ETB to a molecular weight of 558 bp. (a) ETA and ETB transcripts amplified by RT-PCR in
fibroblasts and neutrophils. Lane 1: molecular weight ladder; lane 2: negative control; lane 3: fibroblasts (ETA); lane 4: neutrophils (ETA), lane
5: negative control; lane 6: fibroblasts (ETB); lane 7: neutrophils (ETB). (b) ETA transcripts amplified by RT-PCR in T lymphocytes, activated
T cells, and fibroblasts. Lane 1: T lymphocytes; lane 2: activated T cells; lane 3: fibroblasts; lane 4: negative control, lane 5: molecular weight
ladder. (c) ETB transcripts amplified by RT-PCR in T lymphocytes, activated T lymphocytes, and fibroblasts. Lane 1: negative control; lane 2:
T lymphocytes; lane 3: activated T cells; lane 4: fibroblasts; lane 5: molecular weight ladder.
Table 2: ETA and ETB expression on T lymphocytes and monocytes in relation to the clinical features of the disease, such as cutaneous form
and presence or absence of PAH, ILD, and DUs.
T lymphocytes Monocytes
ETA ETB ETA ETB
lSSc (𝑛 = 32)/dSSc
(𝑛 = 9) 99.1 ± 42.1/94.8 ± 48.2
51.9 ± 31.1/28.6 ± 17.9
(𝑃 < 0.01) 199.3 ± 34.5/251.2 ± 16.3
97.2 ± 24.5/74.4 ± 29.6
(𝑃 < 0.05)
PAH
presence/absence 102.6 ± 45.3/104.7 ± 40.9 47.2 ± 26.8/44.9 ± 30.1 202.7 ± 31.4/200.8 ± 30.9 77.2 ± 23.4/96.9 ± 27.3
ILD presence/absence 111.6 ± 43.9/77.8 ± 34.2(𝑃 < 0.05) 44.8 ± 27.3/45.3 ± 21.6 199.8 ± 56.5/211.2 ± 47.3 90.6 ± 26.5/89.7 ± 31.7
DUs
presence/absence 121.4 ± 69/98.8 ± 41.6 40.8 ± 20.1/48.6 ± 31 221 ± 4.3/196.2 ± 69.6 80.4 ± 25.3/93.6 ± 27.5
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Table 3: Detection of cytokines in the supernatants of CD4+ T lymphocytes after 24 hours of incubation with ET-1 alone or with selective or
dual receptors blockade. One million cells were incubated in each cell culture condition.
Control cells Cells with ET-1 Cells with ET-1 andETA antagonist
Cells with ET-1 and
ETB antagonist
Cells with ET-1 and
dual receptor
blockade
INF-𝛾 (pg/mL) 0.8 ± 0.2 7.6 ± 0.2 1.2 ± 0.45 1.6 ± 0.6 0 ± 0.1
IL-4 (pg/mL) 78.1 ± 74.3 60.8 ± 80.2 711.42 ± 102.2 694.47 ± 99.8 682 ± 100.6
IL-17 (pg/mL) 28.7 ± 10.2 36.1 ± 11.1 37.2 ± 9.8 35.6 ± 12.3 36.6 ± 10.8
Table 4: Molecules detected in neutrophils supernatants after 1, 3, or 10 hours of incubation with either no stimulus or ET-1, LPS, and ET-1
plus LPS, respectively.
No stimulus ET-1 LPS ET-1 + LPS
Time of incubation 1 3 10 1 3 10 1 3 10 1 3 10
IL8 (pg/mL) 5.38 6.92 16.92 7.69 7.69 16.92 31.54 59.23 93.85 18.46 67.69 134.6
TNF𝛼 (pg/mL) 0 0 0 0 0 23.4 0 0 0 0.7 0 2.1
MMP9 (ng/mL) 46.4 67.8 58.8 165.1 64.7 63.3 131.3 203.8 205.3 102.9 205.6 220.7
VEGF (pg/mL) 18.58 20.42 28.75 16.25 22.1 28.7 33.75 52.92 57.92 32.08 54.58 56.25
INF𝛾 (pg/mL) 0.28 0 0 1.94 0 0.28 14.17 0 0 0 0 0
IL17 (pg/mL) 0 0 0 0 0 3.5 0 0 0 0 0 0
of disease and were not influenced by the presence of PAH,
ILD, and DUs.
Neutrophils presented the same pattern of expression of
ET-1 receptors in SSc patients and control subjects (Table 1).





T CD4+ and CD8+ Cells. As already shown on the entire T
cell population, both CD4+ and CD8+ T cell subsets isolated
from SSc patients and control healthy donors express ETA
and ETB on their surface. A higher ETA expression on resting
CD4+ andCD8+T cells was also confirmed.Upon activation,
we found a decreased expression of ETA and an increased
expression of ETB (Figure 3).





Stimulation by ET-1. We tested the levels of INF-𝛾, IL-
4, and IL-17 in the supernatants of CD4+ T cells obtained
from SSc patients and controls. Cells were either incubated
without any stimulus or incubated with ET-1 in the presence
or absence of ET-1 receptors blockade. After 24 hours of
incubation with ET-1, INF-𝛾 concentration was 9.5 times
higher than in the supernatants of cells cultured without
ET-1 (7.6 pg/mL versus 0.8 pg/mL; 𝑃 < 0.05). Following
selective ETA or ETB blockade before ET-1 stimulation,
INF-𝛾 levels decreased to 1.2 and 1.6 pg/mL, respectively.
Remarkably, the simultaneous dual ET-1 receptors blockade,
which mimics in vitro the effects of bosentan treatment,
caused a marked reduction of INF-𝛾 concentrations in the
cells culture supernatants. Interleukin-4 levels did not change
in the supernatant of cells exposed to ET-1 for 24 hours. In the
presence of selective inhibition of ETA, IL-4 levels increased
in a more significant manner than in the presence of ETB
blockade (711.42 ± 102.2 pg/mL and 694.47 ± 99.8 pg/mL,
resp., versus 60.8 ± 80.2; 𝑃 = 0.018 and 𝑃 < 0.01). Also,
the double receptors blockade induced the production of
IL-4 (682 ± 100.6 pg/mL versus 60.8 ± 80.2 pg/mL; 𝑃 =
0.02). Remarkably, we observed a slight increase in IL-17 level
following the incubation with ET-1. However, this effect was
not modified by partial or complete ET-1 receptor blockade
(Table 2).




Stimulation by ET-1. Levels of MMP-9, IL-8, TNF-𝛼, VEGF,
IFN-𝛾, and IL-17 were evaluated in the medium of neu-
trophils isolated from 4 healthy donors incubated with ET-1
or LPS or with ET-1 and LPS for 1, 3, or 10 hours (Table 3).
A 1-hour incubationwith ET-1 induced amarked increase
of MMP-9 (165.1 ng/mL versus 46.4 ng/mL; 𝑃 < 0.05),
whereas, at the same time point, we did not observe sig-
nificant changes in the production of the other soluble
molecules analysed, as shown in Table 4. After 3 hours of
incubation with both ET-1 and LPS, neutrophils released a
higher amount of IL-8 when compared to the concentration
detected following the incubation with ET-1 alone or LPS
alone (67.7 versus 7.7 versus 59.2 pg/mL, resp.), whereas the
levels of the other soluble mediators remained unchanged.
The concentration of TNF-𝛼 released in the supernatants
following a 10-hour incubation with ET-1 was higher than
the levels detected in the medium of cells stimulated with
ET-1 and LPS or LPS alone (23.4 pg/mL versus 2.1 pg/mL
versus undetectable level; 𝑃 < 0.05). At the same time point,
incubation with ET-1 alone induced a higher production
of IL-17 compared to the stimulation with both ET-1 and
LPS or LPS alone (3.5 pg/mL versus undetectable level;
𝑃 < 0.05). Finally, the simultaneous stimulation with ET-
1 and LPS induced a higher secretion of IL-8 and MMP-
9 in the supernatant (134.6 pg/mL and 220.7 ng/mL, resp.)
when compared to the concentration reached with ET-1
(16.6 pg/mL and 63.7 ng/mL, resp.) or LPS alone (93.8 pg/mL
and 205.3 ng/mL, resp.).


































































































































Figure 3: Change in ETA and ETB expression on activated T CD4+ and CD8+ cells. The stimulation of cells, performed with microbeads
coated by anti-CD3/CD28 antibodies, leads to a reduction of ETA and an increase of ETB expression, both in CD4+ (a-b; c-d) and CD8+ cells
(e-f; g-h), respectively. The profile of one of ten similar experiments is shown.
Taken together, these data indicate that ET-1 is able to
induce neutrophils to release proinflammatory mediators.
4. Discussion
In the present study, we aimed firstly at analysing the cellular
surface distribution of ET-1 receptors in the different immune
cell subsets and secondly at dissecting the mechanisms by
which the ET-1 signalling network may participate in the
inflammatory responses in SSc.
ET-1 is a potent vasoconstrictor which plays a funda-
mental role in key pathogenetic aspects of SSc such as
vascular damage and fibrosis and treatment with ERAs exerts
beneficial effects on vasculopathy [36, 37]. More recently,
amelioration of inflammatory parameters during ERA treat-
ment has been reported (reviewed in [44]), thus implying an
important role for ET-1 in inflammation, another important
aspect of SSc pathology. Indeed inflammation plays a pivotal
role in early SSc [45]; however, it may influence also different
phases of SSc.
The presence of ET-1 receptors on dendritic cells and
polymorphonuclear cells has been already reported [6–8, 16],
often with conflicting results, whereas very little is known
on ETA and ETB expression on T and B lymphocytes.
Moreover, a proinflammatory role for ETB expressed by
monocytes/macrophages has been hypothesized on the basis
of increased production of inflammatory mediators (TNF-𝛼,
prostaglandin E2, and IL-1𝛽) upon ET-1 stimulation [11, 44].
We show here that all the immune cells studied (B and
T lymphocytes, monocytes, and neutrophils) express ET-1
receptors both in normal subjects and in SSc patients with
a difference in the relative expression of either ETA or ETB in
the different cell types analysed. In particular, B lymphocytes
and neutrophils show the same pattern of expression in
healthy controls and in SSc patients, without any significant
difference related to the clinical features of the disease. T
lymphocytes andmonocytes express a higher ETA expression
than ETB on both subsets. Since ET-1 serum levels are higher
in dSSc than lSSc patients and they correlatewith the extent of
vascular damage and cutaneous fibrosis, we may hypothesize
that at least part of ET-1 profibrotic effects is preferentially
mediated by the engagement of ETA [3, 16].
Interestingly, we noticed that, in lSSc patients, a lower ETB
expression onmonocytes correlates with the presence of PAH
and a lower ETA expression onT cells correlates with ILD.We
can therefore hypothesize that a different pattern of receptor
expression on immune cells is associated with a different
functional activity that may contribute to the development of
PAH or ILD.
A recent multicenter, placebo-controlled trial investigat-
ing new drug therapies for idiopathic pulmonary fibrosis
compared the effects of ambrisentan, a selective ETA antag-
onist, to placebo on disease progression. The study showed
that the treatment was associated with an accelerated decline
in pulmonary function tests, increased hospitalizations, and
higher mortality [46]. Since a selective ETA inhibition, such
as the one obtained with ambrisentan, seems to accelerate
pulmonary disease, we may suggest that an imbalanced
expression of ET-1 receptors with a diminished expression of
ETA on immune cells may predispose SSc patients to develop
ILDpossibly through an increasedETB-mediated stimulation
on T cells. The results of this study are in accordance with
our findings of a lower ETA expression on T cells of SSc
patients with ILD. However, the precise role played by ETA
stimulation and inhibition in the progression of pulmonary
fibrosis remains unclear.
We next evaluated whether the presence of an inflamma-
tory microenvironment could influence the relative expres-
sion and/or distribution of ET-1 receptors and, to this aim,
we stimulated T cells with anti-CD3/CD28 antibody-coated
10 Journal of Immunology Research
microbeads. Stimulation resulted in reduced expression of
ETA and increased expression of ETB on CD4+ and CD8+
T cells, thus suggesting that these cells, once activated,
modulate receptor surface expression by overexpressing ETB
and downregulating ETA. These results support the hypoth-
esis that ETB signalling plays a major role in inflammation
and, as a consequence, that dual ET-1 receptors blockade
may represent a more suitable therapeutic strategy in SSc.
We have then investigated the functional effects of ET-1
stimulation on CD4+ T cells and found that ET-1 is able to
induce a proinflammatory response since the engagement
of both ETA and ETB induced an IFN-𝛾 secretion 9.5 times
higher than the one observed in basal condition. IFN-𝛾
production was markedly reduced following dual receptor
blockade, a situation which resembles the effect of bosentan
treatment. These findings suggest the need of ETA-ETB
receptors cooperation to obtain an inflammatory response in
CD4+ lymphocytes. These results are in agreement with the
observation that simultaneous blockade of both ETA and ETB
in scleroderma fibroblasts is necessary in order to suppress
collagen production [24]. In addition, ET-1 stimulation of
CD4+T cells leads to amild increase of IL-17 concentration in
cell supernatants, suggesting again an important role for ET-
1 in inducing the production of proinflammatory cytokines.
Finally, the receptors blocking induces the production of the
anti-inflammatory cytokine IL-4.
Finally, it is interesting to note that neutrophils activated
with LPS are able to increase the production of proinflam-
matory molecules after stimulation with ET-1, thus giving
further support to the proinflammatory effects of ET-1 also
on cells of innate immunity.
All together, these data indicate that ET-1 behaves also as
a proinflammatory molecule through a synergistic action on
ETA and ETB. Therefore, a dual receptor blockade strategy
is likely to better control inflammation and fibrosis than a
selective receptor blockade. In conclusion, our results, besides
generating useful insight in the understanding of ET-1 effects
on immune cells in healthy donors and in SSc patients,
provide a rationale for the use of dual receptor antagonist in
the early stages of SSc, when inflammation is prominent.
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